RxDoctor Payments Data

Kent Wellish, MD

Ophthalmology · Las Vegas, NVNPI 1952358426

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,902 of the $10,068 with a category attached, or 78.5%. 26 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 29.3% of the total. Reporting peaked in 2019 at $2,942 and has fallen 63.8% since, to $1,065 in 2025.

$10,068in general payments, 2019–2025

Across 222 payments — averaging $45.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$3K
  • Bausch & Lomb Americas Inc.$920
  • Glaukos Corporation$875
  • AbbVie$719
  • Ivantis, Inc$613
  • Novartis$549
  • plus $3K from 20 others
$175,293in research payments, 2019–2025

Across 75 payments — averaging $2337.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$122K
  • Shire North American Group Inc$39K
  • AbbVie$10K
  • Takeda Pharmaceuticals U.S.A., Inc.$5K

What the payments were for

  • Consulting fees$7507%
  • Travel & lodging$1,37714%
  • Food & beverage$7,90278%
  • Entertainment$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,068 in reported general payments places this provider in the 85th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada

Medicare billing

Part B allowed, 2024
$191,606
Medicare patients
427
Services billed
1,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj11$503,568
RestasisCyclosporine27$30,785
CequaCyclosporine35$26,998
ProlensaBromfenac Sodium80$26,972
XiidraLifitegrast27$20,891
MieboPerfluorohexyloctane/Pf21$15,658
Prednisolone Acetate217$15,650
MoxifloxacinMoxifloxacin Hcl230$4,118
ErythromycinErythromycin Base406$3,908
Brimonidine Tartrate13$512
Atropine Sulfate16$487
Latanoprost65$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$327$503,56811 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$920$36,54948 claims
AbbVieRestasis$719$30,78527 claims
Sun Pharmaceutical Industries Inc.Cequa$493$26,99835 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$314$26,97280 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 121 ophthalmology providers in Nevada.

Other ophthalmology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →